PHILADELPHIA, PA--(Marketwire - May 20, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that Gearóid Faherty, Chairman and Chief Executive Officer, is scheduled to present at the following conference:
Event: UBS Global Specialty Pharmaceuticals Conference Date: Tuesday, June 2, 2009 Time: 11:00 a.m. BST (6:00 a.m. ET) Location: The Waldorf Hilton Hotel London, U.K.
An audio webcast of the Company’s presentation will be available by accessing the investor relations section of Eurand’s web site at www.eurand.com and will be available via replay until July 2, 2009.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had five products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. The Company’s technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
Contacts:
Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact
Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact
